JPAD-Journal of Prevention of Alzheimers Disease

Papers
(The TQCC of JPAD-Journal of Prevention of Alzheimers Disease is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease196
Diagnosis of Early Alzheimer’s Disease: Clinical Practice in 2021111
The Epidemiology of Alzheimer’s Disease Modifiable Risk Factors and Prevention92
Lecanemab: Appropriate Use Recommendations75
Aducanumab: Appropriate Use Recommendations57
Aducanumab: Appropriate Use Recommendations Update41
Senolytic Therapy to Modulate the Progression of Alzheimer’s Disease (SToMP-AD): A Pilot Clinical Trial34
Current State of Self-Administered Brief Computerized Cognitive Assessments for Detection of Cognitive Disorders in Older Adults: A Systematic Review26
Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer’s Disease Treated with Anti-Amyloid Beta Therapy21
Donanemab (LY3002813) Phase 1b Study in Alzheimer’s Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging21
Effects of Folic Acid and Vitamin B12 Supplementation on Cognitive Impairment and Inflammation in Patients with Alzheimer’s Disease: A Randomized, Single-Blinded, Placebo-Controlled Trial20
Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force18
Socioeconomic Status and Risks of Cognitive Impairment and Dementia: A systematic Review and Meta-Analysis of 39 Prospective Studies17
Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profiles in Mild Cognitive Impairment and Alzheimer’s Disease15
The Japan-Multimodal Intervention Trial for Prevention of Dementia (J-MINT): The Study Protocol for an 18-Month, Multicenter, Randomized, Controlled Trial12
ITEM-LEVEL INVESTIGATION OF PARTICIPANT AND STUDY PARTNER REPORT ON THE COGNITIVE FUNCTION INDEX FROM THE A4 STUDY SCREENING DATA12
Establishing Clinically Meaningful Change on Outcome Assessments Frequently Used in Trials of Mild Cognitive Impairment Due to Alzheimer’s Disease12
Tackling a Major Deficiency of Diversity in Alzheimer’s Disease Therapeutic Trials: An CTAD Task Force Report11
Effects of Mindfulness-Based Tai Chi Chuan on Physical Performance and Cognitive Function among Cognitive Frailty Older Adults: A Six-Month Follow-Up of a Randomized Controlled Trial10
Detection Rates of Mild Cognitive Impairment in Primary Care for the United States Medicare Population10
Buntanetap, a Novel Translational Inhibitor of Multiple Neurotoxic Proteins, Proves to Be Safe and Promising in Both Alzheimer’s and Parkinson’s Patients10
Representation of Racial and Ethnic Minority Populations in Dementia Prevention Trials: A Systematic Review9
Programmed Death of Microglia in Alzheimer’s Disease: Autophagy, Ferroptosis, and Pyroptosis8
Association of Subjective Cognitive Decline with Risk of Cognitive Impairment and Dementia: A Systematic Review and Meta-Analysis of Prospective Longitudinal Studies8
Antihypertensive Agents and Incident Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Observational Studies7
Immunotherapy for Alzheimer’s Disease: Current Scenario and Future Perspectives7
Using Digital Tools to Advance Alzheimer’s Drug Trials During a Pandemic: The EU/US CTAD Task Force7
Burden of Illness in People with Alzheimer’s Disease: A Systematic Review of Epidemiology, Comorbidities and Mortality7
Major Cost Drivers in Assessing the Economic Burden of Alzheimer’s Disease: A Structured, Rapid Review7
Aging, Senescence, and Dementia7
Childhood Secondhand Smoke Exposure and Risk of Dementia, Alzheimer’s Disease and Stroke in Adulthood: A Prospective Cohort Study7
The Future of AD Clinical Trials with the Advent of Anti-Amyloid Therapies: An CTAD Task Force Report7
Sensitivity of the Preclinical Alzheimer’s Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer’s Disease -Atabece7
Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer’s Disease7
Environmental Distractions during Unsupervised Remote Digital Cognitive Assessment7
Geniposidic Acid Confers Neuroprotective Effects in a Mouse Model of Alzheimer’s Disease through Activation of a PI3K/AKT/GAP43 Regulatory Axis6
Blood Derived Amyloid Biomarkers for Alzheimer’s Disease Prevention6
The Scottish Brain Health Service Model: Rationale and Scientific Basis for a National Care Pathway of Brain Health Services in Scotland6
ACU193, a Monoclonal Antibody that Selectively Binds Soluble Aß Oligomers: Development Rationale, Phase 1 Trial Design, and Clinical Development Plan6
Amyloid and APOE Status of Screened Subjects in the Elenbecestat MissionAD Phase 3 Program6
Clinical Trial Endpoints and Their Clinical Meaningfulness in Early Stages of Alzheimer’s Disease6
Chinese Preclinical Alzheimer’s Disease Study (C-PAS): Design and Challenge from PET Acceptance6
Association of a MIND Diet with Brain Structure and Dementia in a French Population6
The Effects of Dual-Task Training on Cognitive and Physical Functions in Older Adults with Cognitive Impairment; A Systematic Review and Meta-Analysis6
Living Environment, Built Environment and Cognitive Function among Older Chinese Adults: Results from a Cross-Sectional Study5
Sex Moderates the Association between Frailty and Mild Behavioral Impairment5
Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force5
Disease Burden and Attributable Risk Factors of Alzheimer’s Disease and Dementia in China from 1990 to 20195
Protocol for the Brain Health Support Program Study of the Canadian Therapeutic Platform Trial for Multidomain Interventions to Prevent Dementia (CAN-THUMBS UP): A Prospective 12-Month Intervention St5
‘Time Saved’ As a Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings5
Tauroursodeoxycholic Acid Attenuates Diet-Induced and Age-Related Peripheral Endoplasmic Reticulum Stress and Cerebral Amyloid Pathology in a Mouse Model of Alzheimer’s Disease5
POSTERS 14th Conference Clinical Trials Alzheimer’s Disease, November 9-12, 2021, Boston, USA5
Editorial: Accelerating Innovations for Enhanced Brain Health. Can Artificial Intelligence Advance New Pathways for Drug Discovery for Alzheimer’s and other Neurodegenerative Disorders?4
Effectiveness of Physical Exercise on Alzheimer’s disease. A Systematic Review4
Aducanumab: Appropriate Use Recommendations4
Cognitive Digital Biomarkers from Automated Transcription of Spoken Language4
The Role of Thyroid Dysfunction in Alzheimer’s Disease: A Systematic Review and Meta-Analysis4
Multimodal Preventive Trial for Alzheimer’s Disease: MIND-ADmini Pilot Trial Study Design and Progress4
Everyday Functioning and Entorhinal and Inferior Temporal Tau Burden in Cognitively Normal Older Adults4
Communicating Personal Risk Profiles of Alzheimer’s Disease to Older Adults: A Pilot Trial4
Are Population-Level Approaches to Dementia Risk Reduction Under-Researched? A Rapid Review of the Dementia Prevention Literature4
Aducanumab Trials EMERGE But Don’t ENGAGE4
Effects of Non-Invasive Brain Stimulation on Alzheimer’s Disease4
Oral Health as a Risk Factor for Alzheimer Disease4
Neuropsychiatric Symptoms in AD: Clinical Trials Targeting Mild Behavioral Impairment: A Report from the International CTAD Task Force4
Digital Screening for Cognitive Impairment – A Proof of Concept Study4
In Vivo Detection of Changes Related to Cortical Columnar Organization and Neuroinflammation Across the AD Continuum4
Cerebral Phospho-Tau Acts Synergistically with Soluble Aβ42 Leading to Mild Cognitive Impairment in AAV-AD Rats4
The Effect of Multidomain Interventions on Global Cognition, Symptoms of Depression and Apathy – A Pooled Analysis of Two Randomized Controlled Trials4
The ‘Aducanumab Story’: Will the Last Chapter Spell the End of the ‘Amyloid Hypothesis’ or Mark a New Beginning?4
Association of Blood MicroRNA Expression and Polymorphisms with Cognitive and Biomarker Changes in Older Adults3
Elevated Blood Homocysteine and Risk of Alzheimer’s Dementia: An Updated Systematic Review and Meta-Analysis Based on Prospective Studies3
Utility of Environmental Complexity as a Predictor of Alzheimer’s Disease Diagnosis: A Big-Data Machine Learning Approach3
Initial Experiences with Amyloid-Related Imaging Abnormalities in Patients Receiving Aducanumab Following Accelerated Approval3
A Polymorphism Cluster at the 2q12 locus May Predict Response to Piromelatine in Patients with Mild Alzheimer's Disease3
Salivary Alpha-Amylase Activity and Mild Cognitive Impairment among Japanese Older Adults: The Toon Health Study3
Study Protocol of a Comprehensive Activity Promotion3
Platform Trials to Expedite Drug Development in Alzheimer’s Disease: A Report from the EU/US CTAD Task Force3
Low Amino Acid Score of Breakfast is Associated with the Incidence of Cognitive Impairment in Older Japanese Adults: A Community-Based Longitudinal Study3
Clinical Implementation of Lecanemab: Challenges, Questions and Solutions3
Recruitment of Older African Americans in Alzheimer’s Disease Clinical Trials Using a Community Education Approach3
Early-Onset Subgroup of Type 2 Diabetes and Risk of Dementia, Alzheimer’s disease and Stroke: A Cohort Study3
Digital Clock Drawing as an Alzheimer’s Disease Susceptibility Biomarker: Associations with Genetic Risk Score and APOE in Older Adults3
What Matters to Patients with Alzheimer’s Disease and Their Care Partners? Implications for Understanding the Value of Future Interventions3
Prediction of Cognitive Decline for Enrichment of Alzheimer’s Disease Clinical Trials3
Digital Therapeutics for MCI and Alzheimer’s disease: A Regulatory Perspective - Highlights From The Clinical Trials on Alzheimer’s Disease conference (CTAD)3
Reproductive Markers in Alzheimer’s Disease Progression: The Framingham Heart Study3
Clinical Research Investigating Alzheimer’s Disease in China: Current Status and Future Perspectives Toward Prevention3
Diagnostic Biomarkers of Amyloid and Tau Pathology in Alzheimer’s Disease: An Overview of Tests for Clinical Practice in the United States and Europe3
Safety, Tolerability, Pharmacokinetics and Quantitative Electroencephalography Assessment of ACD856, a Novel Positive Allosteric Modulator of Trk-Receptors Following Multiple Doses in Healthy Subjects3
Mesenchymal Stem Cells Modulate SIRT1/MiR-134/ GSK3β Signaling Pathway in a Rat Model of Alzheimer's Disease3
Decreased Gray–White Matter Contrast of [11C]-PiB Uptake in Cognitively Unimpaired Subjects with Severe Obstructive Sleep Apnea3
US Adults’ Likelihood to Participate in Dementia Prevention Drug Trials: Results from the National Poll on Healthy Aging3
Editorial: What Are the Remaining Challenges before Blood-Based Biomarkers for Alzheimer’s Disease Can Be Used in Clinical Practice?3
Change on Clinical Trial Outcome Assessments: The Search for Meaningfulness2
Beyond Frailty in Alzheimer’s Disease: Should We Move to the Concept of Intrinsic Capacity?2
Global Energy Metabolism Deficit in Alzheimer Disease Brain2
Determinants of Medical Direct Costs of Care among Patients of a Memory Center2
Associations of Stages of Objective Memory Impairment with Cerebrospinal Fluid and Neuroimaging Biomarkers of Alzheimer’s Disease2
Neuroprotective Effects of IVIG against Alzheimer’ s Disease via Regulation of Antigen Processing and Presentation by MHC Class I Molecules in 3xTg-AD Mice2
Adult Renal Dysfunction and Risk of Dementia or Cognitive Decline: Brain-Kidney Axis Hypothesis Based on a Systematic Review and Meta-Analysis2
Therapeutic Targets for Alzheimer’s Disease: Amyloid Vs. Non-Amyloid. Where Does Consensus Lie Today? An CTAD Task Force Report2
The Community Engaged Digital Alzheimer’s Research (CEDAR) Study: A Digital Intervention to Increase Research Participation of Black American Participants in the Brain Health Registry2
Evidence-Based Tools for Dietary Assessments in Nutrition Epidemiology Studies for Dementia Prevention2
Two-Year Prognostic Utility of Plasma p217+tau across the Alzheimer’s Continuum2
Evaluating Causal Effects of Gut Microbiome on Alzheimer’s Disease2
Association between 9p21-23 Locus and Frailty in a Community-Dwelling Greek Population: Results from the Hellenic Longitudinal Investigation of Ageing and Diet2
A Genetic Validation of the Neurodegeneration Biomarkers Tau-A and Tau-C - A Mendelian Randomization Study2
Pharmacological Inventions for Alzheimer Treatment in the United States of America: A Revision Patent from 2010 – 20202
Anxiety and Depressive Symptoms and Cortical Amyloid-β Burden in Cognitively Unimpaired Older Adults2
The Association between Sugar-Sweetened Beverages and Cognitive Function in Middle-Aged and Older People: A Meta-Analysis2
Cognitive Performance and Incident Alzheimer’s Dementia in Men Versus Women2
Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab2
The Association between Peanut and Peanut Butter Consumption and Cognitive Function among Community-Dwelling Older Adults2
New Hope for Alzheimer’s Disease2
Implications of Emerging Uses of Genetic Testing for Alzheimer’s Disease2
POSTERS - 15th Conference Clinical Trials Alzheimer’s Disease, November 29- December 2, 2022, San Francisco, CA, USA2
Oral Tau Aggregation Inhibitor for Alzheimer’s Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylat2
A UK-Wide Study Employing Natural Language Processing to Determine What Matters to People about Brain Health to Improve Drug Development: The Electronic Person-Specific Outcome Measure (ePSOM) Program2
Anti-Amyloid Therapies for Alzheimer’s Disease: An Alzheimer Europe Position Paper and Call to Action2
Systematic and Comparative Analysis of the Burden of Alzheimer´s Disease and Other Dementias in Mexico. Results at the National and Subnational Levels, 1990-20192
How Modifiable Are Modifiable Dementia Risk Factors? A Framework for Considering the Modifiability of Dementia Risk Factors2
SYMPOSIA - 16th Conference Clinical Trials Alzheimer’s Disease, October 24-27- 2023, Boston, MA, USA2
SYMPOSIA 14th Conference Clinical Trials Alzheimer’s Disease, November 9-12, 2021, Boston, USA2
Female Reproductive Factors and Risk of Mild Cognitive Impairment and Dementia: The HUNT Study2
SYMPOSIA - 15th Conference Clinical Trials Alzheimer’s Disease, November 29- December 2, 2022, San Francisco, CA, USA2
Environmental Enrichment in Murine Models and Its Translation to Human Factors Improving Conditions in Alzheimer Disease2
Mechanisms Underlying Non-Pharmacological Dementia Prevention Strategies: A Translational Perspective2
Phase 1/2a Intravenous and Subcutaneous Oligomer-Specific Antibody KHK6640 in Mild to Moderate Alzheimer’s Disease2
Predicting Progression from Normal to MCI and from MCI to AD Using Clinical Variables in the National Alzheimer’s Coordinating Center Uniform Data Set Version 3: Application of Machine Learning Model2
The SINgapore GERiatric Intervention Study to Reduce Cognitive Decline and Physical Frailty (SINGER): Study Design and Protocol2
A Fay-Herriot Model for Estimating Subjective Cognitive Decline among Military Veterans2
Editorial: Lecanemab: Appropriate Use Recommendations – A Commentary from a European Perspective2
Understanding Barriers and Facilitators to Signing Up for a Mobile-Responsive Registry to Recruit Healthy Volunteers and Members of Underrepresented Communities for Alzheimer’s Disease Prevention Stud2
0.043375015258789